Last reviewed · How we verify
PB 6 doses - Rifampicin and Dapsone
PB 6 doses is a fixed-dose combination of rifampicin and dapsone that inhibits bacterial cell wall and folate synthesis to treat leprosy.
PB 6 doses is a fixed-dose combination of rifampicin and dapsone that inhibits bacterial cell wall and folate synthesis to treat leprosy. Used for Leprosy (paucibacillary and multibacillary forms).
At a glance
| Generic name | PB 6 doses - Rifampicin and Dapsone |
|---|---|
| Also known as | PB 6 doses of 2 drugs |
| Sponsor | University of Brasilia |
| Drug class | Antileprosy combination therapy |
| Target | Bacterial RNA polymerase (rifampicin); dihydropteroate synthase (dapsone) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Rifampicin inhibits bacterial RNA polymerase, disrupting transcription in Mycobacterium leprae, while dapsone inhibits dihydropteroate synthase in the folate synthesis pathway. Together, these agents provide synergistic bactericidal and bacteriostatic activity against the causative agent of leprosy, reducing bacterial load and preventing resistance.
Approved indications
- Leprosy (paucibacillary and multibacillary forms)
Common side effects
- Hemolytic anemia
- Hepatotoxicity
- Peripheral neuropathy
- Gastrointestinal disturbance
- Methemoglobinemia
Key clinical trials
- Uniform Multidrug Therapy Regimen for Leprosy Patients (PHASE4)
- Virgin Coconut Oil Oral Supplementation for Leprosy Patients (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PB 6 doses - Rifampicin and Dapsone CI brief — competitive landscape report
- PB 6 doses - Rifampicin and Dapsone updates RSS · CI watch RSS
- University of Brasilia portfolio CI